BD (Becton, Dickinson and Company), a staple in global medical technology, embarks on a pivotal journey with the XTRACT™ Registry, aiming to pioneer substantial breakthroughs in understanding peripheral artery disease (PAD). As the inaugural patient steps into this extensive research, the focus intensifies on collecting crucial insights required to amplify real-world medical strategies. The pioneering study, led by interventional cardiologist Dr. Prakash Krishnan and vascular surgeon Dr. Todd Berland, promises to shed light on the dynamic potentials of the Rotarex™ Catheter System.
First Patient Enrollment Sets the Pace
On September 29, 2025, the groundbreaking XTRACT™ Registry saw its first patient enrolled under Dr. Kousta Foteh at the Vital Heart & Vein medical practice. This milestone marks the onset of a comprehensive data collection venture designed to refine PAD treatment frameworks nationwide. The registry promises to enroll up to six hundred participants across one hundred U.S. sites, with each patient contributing valuable information through follow-up assessments at 30 days, six months, and one year post-procedure.
Innovative Technology at the Forefront
The Rotarex™ Catheter System is engineered to adeptly clear plaque and thrombus using a three-pronged approach, making it indispensable for treating various PAD lesions. Blending the functionalities of both atherectomy and thrombectomy, the system’s rotating atraumatic head and internal helix actively work to aspirate material, ensuring effective treatment outcomes. The enrollment of the first patient represents BD’s dedication to gathering substantial clinical evidence to back this innovation, thereby furthering PAD care and elevating patient prognoses.
– A critical leap in advancing real-world PAD data through extensive registry setup
– Pioneering efforts by BD in strengthening the research and management of PAD
– The Rotarex™ Catheter System’s distinct features potentially revolutionizing PAD treatment.
As over 21 million Americans, alongside a global figure exceeding 200 million, grapple with PAD, BD’s commitment becomes more visible with initiatives like the XTRACT™ Registry. The company’s ongoing pursuit to integrate innovative technology with real-world clinical applications sets a benchmark in PAD treatment methodologies. Through collaborations and extensive research, BD not only aspires to refine PAD care but also encourages medical advancements that bear great promise for numerous patients worldwide. By prioritizing data-driven strategies, BD continues to foster a landscape where medical outcomes are progressively enhanced, cost-efficiency is maximized, and patient access to essential health care is broadened.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
